We are live on ! Find out more

FPRX

Five Prime Therapeutics, Inc.

FPRX

Delisted

FPRX was delisted on the 15th of April, 2021.

103 hedge funds and large institutions have $105M invested in Five Prime Therapeutics, Inc. in 2019 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 44 increasing their positions, 23 reducing their positions, and 24 closing their positions.

New

Increased

Maintained

Reduced

Closed

91% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 23

10% less funds holding

Funds holding: 114 → 103 (-11)

37% less capital invested

Capital invested by funds: $167M → $105M (-$62.3M)

46% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 24

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $500K

Holders

103

Holders Change

-11

Holders Change %

-9.65%

% of All Funds

2.26%

Holding in Top 10

–

Holding in Top 10 Change

–

Holding in Top 10 Change %

–

% of All Funds

–

New

Increased

Reduced

Closed

Calls

–

Puts

$500K

Net Calls

-$500K

Net Calls Change

-$258K

Top Buyers

Rank	Fund	Capital Flow
1	BI BVF Inc San Francisco, California	+$4.18M
2	RSCM Rock Springs Capital Management Baltimore, Maryland	+$1.37M
3	Renaissance Technologies New York	+$1.02M
4	Man Group London, United Kingdom	+$968K
5	Squarepoint New York	+$952K

Top Sellers

Rank	Fund	Capital Flow
1	Fidelity Investments Boston, Massachusetts	-$8.27M
2	GPP Great Point Partners Greenwich, Connecticut	-$3.3M
3	Wellington Management Group Boston, Massachusetts	-$2.69M
4	Axa Paris, France	-$1.33M
5	Goldman Sachs New York	-$906K

#	Name	Holding	Trade Value	Shares Change	Change in Stake
26	26 Squarepoint New York	$805K	+$952K	+173,581	+507%
27	27 Two Sigma Advisers New York	$777K	+$78.5K	+14,300	+8%
28	28 D.E. Shaw & Co New York	$747K	+$582K	+106,048	+122%
29	PIM 29 Platinum Investment Management Sydney Australia 2000, Australia	$741K	–	–	–
30	30 Two Sigma Investments New York	$695K	-$338K	-61,677	-26%
31	31 Morgan Stanley New York	$624K	-$533K	-97,137	-38%
32	32 Bank of New York Mellon New York	$612K	-$13.4K	-2,450	-2%
33	33 Acadian Asset Management Boston, Massachusetts	$606K	+$69.8K	+12,713	+9%
34	WCM 34 Weld Capital Management New York	$598K	+$216K	+39,345	+34%
35	ARTA 35 A.R.T. Advisors New York	$533K	+$181K	+33,000	+32%
36	36 AQR Capital Management Greenwich, Connecticut	$533K	+$755K	+137,571	New
37	37 Jacobs Levy Equity Management Florham Park, New Jersey	$470K	+$455K	+82,983	+217%
38	38 UBS Group Zurich, Switzerland	$462K	+$643K	+117,135	+5,637%
39	39 Macquarie Group Sydney, NSW 2000, Australia	$388K	–	–	–
40	40 Tudor Investment Corp Stamford, Connecticut	$355K	+$9.88K	+1,800	+2%
41	AGA 41 Altrinsic Global Advisors Stamford, Connecticut	$349K	–	–	–
42	PP 42 PDT Partners New York	$342K	+$485K	+88,300	New
43	43 Goldman Sachs New York	$333K	-$906K	-165,075	-66%
44	44 Wells Fargo San Francisco, California	$278K	-$40.9K	-7,453	-9%
45	45 Susquehanna International Group Bala Cynwyd, Pennsylvania	$260K	-$41.9K	-7,635	-10%
46	AG 46 Algert Global San Francisco, California	$248K	+$91.3K	+16,640	+35%
47	47 AllianceBernstein Nashville, Tennessee	$234K	–	–	–
48	48 RhumbLine Advisers Boston, Massachusetts	$222K	+$25.6K	+4,657	+9%
49	49 Swiss National Bank Zurich, Switzerland	$218K	–	–	–
50	PPA 50 Parametric Portfolio Associates Seattle, Washington	$218K	+$62.9K	+11,459	+26%

FPRX Hedge Fund Activity: Q3 2019 in Review

103 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Five Prime Therapeutics, Inc. (FPRX) for Q3 2019, worth a combined $105M — down 37% from $167M a quarter earlier.

Sellers outnumbered buyers: 24 funds closed out of FPRX and 13 opened new positions — a net loss of 11 holders — while 23 trimmed existing stakes and 44 added.

The largest buyer was BVF Inc, adding an estimated $4.18M. The largest seller was Fidelity Investments, cutting an estimated $8.27M.

103 institutional investors held Five Prime Therapeutics, Inc. (FPRX) as of Q3 2019, down from 114 in Q2 2019.
Funds reported $105M of Five Prime Therapeutics, Inc. stock for Q3 2019, down 37% quarter-over-quarter.
13 funds opened new Five Prime Therapeutics, Inc. positions in Q3 2019 and 24 closed out, a net change of -11 holders.
The largest Five Prime Therapeutics, Inc. buyer in Q3 2019 was BVF Inc, an estimated $4.18M added.
The largest Five Prime Therapeutics, Inc. seller in Q3 2019 was Fidelity Investments, an estimated $8.27M sold.

Based on aggregated 13F filings for Q3 2019.

Five Prime Therapeutics, Inc. FPRX